(Q53998750)
Statements
Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. (English)
Mortensen L
Charles P
Bekker PJ
Digennaro J
Johnston CC Jr
1 February 1998
83
2
396-402